Warp Sciences raises $215 million: Kevin Weil's AI-and-robotics chemistry lab wants to bring drug-development work back from China

Warp Sciences, the startup Kevin Weil founded after leaving OpenAI, came out of stealth on October 22, 2026, with a $215 million Series A led by Lightspeed Venture Partners. Bloomberg reported that the round values the company at $865 million including the new money. Warp says it will make and test drug molecules for other companies in automated US labs, with AI models trained on what its experiments produce. The pitch leans on a supply-chain worry: much of this chemistry has long been outsourced to China.

This story is based on Warp's website, OpenAI's GPT-Rosalind announcement, law-firm summaries of the BIOSECURE Act, and reporting by Bloomberg (via The Next Web and Techmeme), TechCrunch and Pharma Manufacturing, checked October 23, 2026. Bloomberg's own article couldn't be read for this story; its details are attributed through The Next Web. Weil left OpenAI the same spring it closed other projects, including Sora, as our Sora shutdown story explains.

The short version

• Money: $215 million Series A, led by Lightspeed; $865 million post-money valuation, per Bloomberg.
• Business: a preclinical chemistry contract research organization (CRO) in the US. Warp says it isn't developing drugs of its own.
• Founders: Kevin Weil (CEO), Sol Reisberg (chief scientific officer), DJ Patil (COO) and Manohar Paluri (CTO).
• China angle: drugmakers have relied on Chinese CROs such as WuXi AppTec; a US law passed in December 2025 starts restricting federal contracts tied to "biotechnology companies of concern."

What does Warp Sciences do?

Warp doesn't try to discover new drugs. Its site describes it as a US chemistry CRO that "makes the molecules that drug discovery teams need," combining chemists, AI and robotics. According to The Next Web's account of Bloomberg's report, Warp targets the step after researchers find a promising molecule: making hundreds or thousands of variants to improve how it works and reduce side effects.

The company says it is building automated labs where "AI designs experiments, robots execute the work, and every result makes the entire system smarter." It says those labs will "capture what was tried and what happened—including the failures—at enormous scale" and turn that into training data. Bloomberg reported that the team of about 20 has already bought robotic arms and AI chips, and that its chemists wear cameras and pressure-sensing gloves during experiments to generate training data. Warp says it is working with a small number of design partners in biotech and pharma.

Weil told Bloomberg that AI hasn't yet changed chemistry the way it has changed software engineering and math, because the field depends far more on experiments: "The models need to see that data." Whether AI agents can do independent research is still contested; Epoch AI's test of that question is covered in our InnovationEval story.

Who is behind Warp, and who invested?

Lightspeed led the round, with IVP, Premji Invest and Lux Capital, per Bloomberg. Warp's site lists more than a dozen other firms, including Mayfield, Menlo Ventures and Conviction. Its angel investors include OpenAI CFO Sarah Friar, OpenAI chief research officer Mark Chen, Anthropic Labs co-lead Mike Krieger, Coinbase CEO Brian Armstrong and LinkedIn co-founder Reid Hoffman.

What did Kevin Weil do at OpenAI?

Weil announced he was leaving OpenAI on April 17, 2026, TechCrunch reported. He had been chief product officer, then moved to the research team and started OpenAI for Science, the group behind Prism, an AI workspace for scientific work. In his departure post, Weil said the group was being absorbed into "other research teams." TechCrunch tied the exit to OpenAI cutting what it called "side quests."

His team's last release came the day before: on April 16, 2026, OpenAI introduced GPT-Rosalind, a reasoning model for biology, drug discovery and translational medicine. OpenAI says it is available to eligible organizations through a trusted-access program, with partners including Amgen, Moderna and Thermo Fisher Scientific. TechCrunch also noted that Weil had deleted a post claiming GPT-5 had solved 10 unsolved Erdős problems, after the claim was challenged.

Why does China matter for drug chemistry?

Drugmakers have long outsourced this kind of work to Chinese firms, especially WuXi AppTec, because it's cheaper and faster, Bloomberg reported. Some worry about sharing sensitive data with Chinese contractors. Warp's own pages don't mention China; they speak of building "the capacity to do it here in America."

US moves on Chinese biotech suppliers, and Warp's launch

1. Dec. 18, 2025BIOSECURE Act signed as Section 851 of the FY2026 defense billBaker McKenzie; Arnold & PorterConfirmed
2. June 8, 2026Pentagon adds WuXi AppTec to its 1260H list of Chinese military companiesArnold & PorterConfirmed
3. Aug. 7, 2026Judge Boasberg blocks enforcement of WuXi's listing while the case proceedsPharma ManufacturingConfirmed
4. Oct. 22, 2026Warp Sciences launches with a $215 million Series ABloomberg via The Next WebReported
5. Dec. 18, 2026Deadline for the federal list of biotechnology companies of concernBaker McKenzie; Arnold & PorterExpected

• Confirmed
• Reported
• Expected

The BIOSECURE Act became law as Section 851 of the National Defense Authorization Act for fiscal 2026, signed December 18, 2025, according to Baker McKenzie. It bars federal agencies from buying biotechnology equipment or services from a "biotechnology company of concern," and from contracting with companies that use such services on federal work. A company on the Pentagon's 1260H list that works in biotechnology qualifies. The Office of Management and Budget must publish the first list by December 18, 2026, per Arnold & Porter. The bans take effect only after federal procurement rules are revised, and existing contracts get a five-year grandfathering period.

On June 8, 2026, the Pentagon added WuXi AppTec to the 1260H list. On August 7, Chief Judge James Boasberg of the US District Court for the District of Columbia granted WuXi a preliminary injunction blocking the designation while its lawsuit proceeds, finding the listing likely "arbitrary and capricious," Pharma Manufacturing reported. The federal government's wider effort to cut Chinese AI from its systems is covered in our DeepSeek ban story.

What's confirmed, reported and uncertain

• Confirmed (Warp): what the company does, its leadership, location and investor list.
• Confirmed (OpenAI, court reporting, law-firm summaries): GPT-Rosalind's April 16 launch; the BIOSECURE Act's date and structure; WuXi's listing and injunction.
• Reported (Bloomberg via The Next Web and Techmeme; TechCrunch): the round size, lead investor, $865 million valuation, team size, lab details, Weil's quote and his OpenAI history.
• Uncertain: when Warp's automated lab will be running at scale, who its customers are, and whether WuXi stays on the 1260H list and becomes a company of concern. This story describes a funding round; it isn't investment advice.